神经分泌生物科学

最新新闻

• 评级变动
  J.P. Morgan Reaffirms Their Buy Rating on Neurocrine (NBIX)
  TipRanks · 2026/8/7
• 评级变动
  J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $217
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Raises Target Price to $183
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $210
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  Bernstein Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $218
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Citi Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $253
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 评级变动
  Deutsche Bank Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Cuts Target Price to $165
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $214
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• UBS Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $214
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $194 to $249
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• Guggenheim Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $207
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• 评级变动
  BMO Capital Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Maintains Target Price $190
  \u5e02\u573a\u8d44\u8baf · 2026/8/18
• 评级变动
  RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $198
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $187
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  Evercore Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $215
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Maintains Target Price $182
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• 评级变动
  Neurocrine (NBIX) Receives a Buy From CCB Intl.
  TipRanks · 2026/9/21
• 评级变动
  Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Cuts Target Price to $182
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Citi Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $253
  \u5e02\u573a\u8d44\u8baf · 2026/9/4
• 评级变动
  Bernstein Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $218
  \u5e02\u573a\u8d44\u8baf · 2026/9/26
• 评级变动
  A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $196 to $225
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $190 to $249
  \u5e02\u573a\u8d44\u8baf · 2026/8/1
• 评级变动
  CCORF Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $210
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 评级变动
  Citi Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $249
  \u5e02\u573a\u8d44\u8baf · 2026/8/3

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。